Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections
Date:
05/06/2026
Citation:
Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD. Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections. Antimicrob Agents Chemother. 2026 May 6;70(5):e0160225. doi: 10.1128/aac.01602-25. Epub 2026 Mar 23. PMID: 41870149; PMCID: PMC13148039.
Abstract
Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations (Klebsiella pneumoniae) and R2 loop structural changes in AmpC (Enterobacter cloacae complex).